



BOX RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: P. Schultz et al. Attorney Docket No.: CHIR116472
Application No.: 09/707,548 Group Art Unit: 1624
Filed: November 6, 2000 Examiner: M.L. Berch
Title: INHIBITORS OF GLYCOGEN SYNTHASE 3 KINASE

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

October 17, 2002


TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 08/948,887, filed October 10, 1997. The references listed on the attached form were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application.
2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of an RCE.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Box RCE, the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on the below date.


Date:

10/17/02


Carol Guljan

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: P. Schultz et al. Attorney Docket No. CHIR116472
Application No.: 09/707,548 Group Art Unit: 1624
Filed: November 6, 2000 Examiner: M.L. Berch
Title: INHIBITORS OF GLYCOGEN SYNTHASE 3 KINASE

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
	U1	5,837,853		11/17/1998	Takashima et al.
	U2	5,866,702		02/02/1999	Mackman et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
	F1	EP 616,032		09/21/1994	Europe		
	F2	WO 97/16452		05/09/1997	WIPO		
	F3	WO 97/22360		06/26/1997	WIPO		
	F4	WO 97/41854		11/13/1997	WIPO		

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
	O1	Anderton et al., "Modulation of PHF-Like Tau Phosphorylation in Cultured Neurones and Transfected Cells," <i>Neurobiology of Aging</i> 16(3):389-402, 1995.
	O2	Borthwick et al., "Inhibition of Glycogen Synthase Kinase-3 by Insulin in Cultured Human Skeletal Muscle Myoblasts," <i>Biochemical and Biophysical Research Communications</i> 210(3):738-745, May 25, 1995.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- _____ O3 Briscoe et al., "A Kinases for Cell-Fate Determination?" *Current Biology* 5(3):228-231, 1995.
- _____ O4 Havlíček et al., "Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds," *J. Med. Chem.* 40:408-412, 1997.
- _____ O5 Imahori et al., "Physiology and Pathology of Tau Protein Kinases in Relation to Alzheimer's Disease," *J. Biochem.* 121(2):179-188, 1997.
- _____ O6 Klein and Melton, "A Molecular Mechanism for the Effect of Lithium on Development," *Proc. Natl. Acad. Sci. USA* 93:8455-8459, August 1996.
- _____ O7 Latimer et al., "Stimulation of MAP Kinase by v-raf Transformation of Fibroblasts Fails to Induce Hyperphosphorylation of Transfected Tau," *FEBS Letters* 365:42-46, 1995.
- _____ O8 Lovestone et al., "Alzheimer's Disease-Like Phosphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells," *Current Biology* 4(12):1077-1086, 1994.
- _____ O9 Massillon et al., "Identification of the Glycogenic Compound 5-Iodotubercidin as a General Protein Kinase Inhibitor," *Biochem. J.* 299:123-128, 1994.
- _____ O10 Normon et al., "A Structure-Based Library Approach to Kinase Inhibitors," *J. Am. Chem. Soc.* 118:7430-7431, 1996.
- _____ O11 Pelech, "Networking With Proline-Directed Protein Kinases Implicated in Tau Phosphorylation," *Neurobiology of Aging* 16(3):247-256, 1995.
- _____ O12 Saran, "Antidiabetic Effects of Lithium," *J. Clin. Psychiatry* 43(9):383-384, September 1982.
- _____ O13 Sperber et al., "Glycogen Synthase Kinase-3 β Phosphorylates Tau Protein at Multiple Sites in Intact Cells," *Neuroscience Letters* 197:149-153, 1995.
- _____ O14 Stambolic et al., "Lithium Inhibits Glycogen Synthase Kinase-3 Activity and Mimics Wingless Signalling in Intact Cells," *Current Biology* 6(12):1664-1668, 1996.
- _____ O15 Sutherland et al., "Inactivation of Glycogen Synthase Kinase-3 β by Phosphorylation: New Kinase Connections in Insulin and Growth-Factor Signalling," *Biochem. J.* 296:15-19, 1993.

- _____ O16 Takashima et al., "Amyloid β Peptide Induces Cytoplasmic Accumulation of Amyloid Protein Precursor via Tau Protein Kinase I/glycogen Synthase Kinase-3 β in Rat Hippocampal Neurons," *Neuroscience Letters* 198:83-86, 1995.
- _____ O17 Takashima et al., "Exposure of Rat Hippocampal Neurons to Amyloid β Peptide (25-35) Induces the Inactivation of Phosphatidyl Inositol-3 Kinase and the Activation of Tau Protein Kinase I/glycogen Synthase Kinase-3 β ," *Neuroscience Letters* 203:33-36, 1996.
- _____ O18 Takashima et al., "Tau Protein Kinase I Is Essential for Amyloid β -Protein-Induced Neurotoxicity," *Proc. Natl. Acad. Sci. USA* 90:7789-7793, August 1993.
- _____ O19 Veselý et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogs," *Eur. J. Biochem.* 224:771-786, 1994.
- _____ O20 Welsh et al., "GSK3: a SHAGGY frog story," *Trends in Cell Biology* 6(7):274-279, 1996.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DKS:cj/skg

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100